Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ARTES has enabled the development and commercialization of multiple recombinant protein products—including vaccines—using its proprietary microbial platforms. Its technologies have supported products approved by EMA and US FDA as well as in non-regulated markets. The company licenses out ready-to-use processes that have been validated for regulatory compliance.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ARTES Biotechnology GmbH.